Medline Industries, LP v. C.R. Bard, Inc.

District Court, N.D. Illinois·Decided August 2, 2019·No. 1:16-cv-03529·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

MEDLINE INDUSTRIES, INC. ) ) Plaintiff, ) ) No. 16 C 3529 v. ) ) District Judge Sharon Johnson Coleman C.R. BARD, INC., ) ) Magistrate Judge Gabriel A. Fuentes Defendant. ) MEMORANDUM OPINION AND ORDER' Before us is a motion to compel by Plaintiff, Medline Industries, Inc., (“Plaintiff’ or “Medline”), asking that the Court order Defendant C.R. Bard, Inc. (“Defendant” or “Bard”) to produce opinions of counsel Bard obtained regarding whether certain of its products infringe Medline patents. (D.E. 209). The matter is now fully briefed, and for the reasons stated herein, we deny Plaintiff's motion to compel. I. Background We set forth only those background facts that are relevant to our decision. Medline has filed three lawsuits” against Bard accusing it of infringing various Medline patents for its medical catheters and related items; included in each complaint is a claim for willful infringement, which carries with it the possibility of enhanced damages pursuant to 35 U.S.C. § 284. (D.E. 1: Complaint). As part of its response to the claim of willful infringement, Bard has asserted the “advice of counsel” defense, stating that it relied on the opinion of counsel that its products do not

'On May 31, 2019, by consent of the parties and pursuant to 28 U.S.C. § 636(c) and Local Rule 73.1, this case was assigned to this Court for all proceedings, including entry of final judgment. (D.E. # 31). ? The instant case, filed in 2016, is known as “Medline II’. The other matters are docketed as case number 14 C 3618 (“Medline I”), and case number 17 C 7216 (“Medline III”).

infringe Medline’s patents. (D.E. 218: Def. Resp. to Mot. at 4). To date, Bard has produced eight opinions that concern each of the patents asserted as being infringed in all three lawsuits Medline has filed against Bard (the “Asserted Patents”). The instant case alleges infringement of three of the Asserted Patents: the ‘352 patent, the ‘452 patent, and the ‘753 patent. (D.E. 91: Amended Complaint PIP 36, 57, 85). Medline contends that it is entitled to additional opinions of counsel obtained by Bard, beyond the eight opinions Bard has produced concerning the Asserted Patents. These additional opinions sought by Medline concern “closely related patents that are identical in the content of their disclosures” to the Asserted Patents, Medline argues. (Pl. Mot. to Compel at 1). Elsewhere in its briefs, Medline explains that the additional opinions it seeks, on unasserted patents, are in the same “patent family” as the Asserted Patents. Medline gives examples of some of these patents, variously describing them as being a “continuation” or “continuation-in-part” of the Asserted Patents; a “division” of the unasserted patents; or as sharing the “same specifications, and similar claim limitations” as the Asserted Patents. (Pl. Mot. to Compel at 2.) Medline states that, accordingly, “the text and drawings of these patents are identical.” (/d.)> Bard does not deny Medline’s characterizations of the asserted and unasserted patents, although it disputes any implication that patents in the same family are subject to particular legal rights or obligations. In its initial memorandum in support of its motion to compel, Medline contends that Bard has refused to acknowledge whether it has received additional opinion letters on the unasserted patents and has refused to produce any additional opinion letters beyond the ones it already has

3 The unasserted patents for which Medline seeks opinion letters from Bard include the ‘812 patent, which is said to be a division of asserted patent ‘452, which itself is said to be a continuation of patent ‘935, asserted in Medline 1, and the ‘756 patent, which is said to be a continuation of the ‘190 patent, also asserted in Medline 1, and which is said to be a continuation-in-part of the ‘761 patent, asserted in Medline III. Bard has produced opinions on the ‘452 patent, the “935 patent, the ‘190 patent, and the ‘761 patent, in addition to other opinions on the patents asserted in the three lawsuits.

produced regarding the Asserted Patents. (P!. Mot. to Compel at 3.) In its response, Bard indicates it did receive opinions on unasserted patents but does not identify how many other opinions it may have obtained or what patents these other opinions concern. (D.E. 218: Def. Resp. to Mot. at 1). Bard objects to producing opinions regarding unasserted patents on the grounds that such opinions are protected by the attorney-client and work-product privilege and that its having produced the eight opinions on the Asserted Patents did not waive any privileges applicable to opinions it received concerning unasserted patents. Whether any privilege waiver has occurred depends largely on whether the opinions Bard seeks to protect are part of the “same subject matter” as the opinions it already produced — thus admittedly waiving privilege — concerning the Asserted Patents. Il. Legal Issues “Federal Circuit law applies when deciding whether particular written or other materials are discoverable in a patent case, if those materials relate to an issue of substantive patent law.” Jn re EchoStar Communications Corp., 448 F.3d 1294, 1298 (Fed. Cir. 2006), citing Advanced Cardiovascular Sys. v. Medtronic, Inc., 265 F.3d 1294, 1307 (Fed. Cir. 2001). A remedy for willful patent infringement is specifically provided for in the Patent Act, see 35 U.S.C. §§ 284— 285; therefore, questions of privilege and discoverability that arise from assertion of the advice- of-counsel defense necessarily involve issues of substantive patent law. See In re Spalding Sports Worldwide, Inc., 203 F.3d 800, 803-04 (Fed. Cir. 2000) (applying Federal Circuit law to question of attorney-client privilege between patent attorney and patentee). A. Willfulness The standard for finding willful infringement of another’s patent was recently revised by the Supreme Court in Halo Electronics, Inc. v. Pulse Electronics, Inc, __ U.S. __, 136 □□ Ct.

1923 (2016). In abrogating the previous two-part test for assessing enhanced willfulness damages set forth in In re Seagate Technology, LLC, 497, F.3d 1360 (Fed. Cir. 2007),* the Court stated that “[t]he sort of conduct warranting enhanced damages has been variously described in our cases as willful, wanton, malicious, bad-faith, deliberate, consciously wrongful, flagrant, or—indeed— characteristic of a pirate.” Halo, 136 S. Ct. at 1932. While district courts have discretion to decide whether an infringer’s behavior rises to that standard, such findings “are generally reserved for egregious cases of culpable behavior.” Jd. A patentee need only show by a preponderance of the evidence that the facts support a finding of willful infringement. Jd. at 1934. See also SRI Int’l Inc. v. Cisco Systems, Inc., 2017-2223, 2019 WL 3162421 (Fed. Cir., July 12, 2019). It is well-settled that an important factor in determining if willful infringement has been shown is whether the alleged infringer obtained an opinion of counsel. Comark Communications, Inc. v. Harris Corp., 156 F.3d 1182, 1191 (Fed. Cir. 1998).

Free access — add to your briefcase to read the full text and ask questions with AI

Medline Industries, LP v. C.R. Bard, Inc., (N.D. Ill. 2019).

Medline Industries, LP v. C.R. Bard, Inc. (Medline Industries, LP v. C.R. Bard, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related